Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 59Gynecologic 52Lymphoid 28Plasma cell 21Sarcoma 14Genitourinary 7Other hematologic neoplasm 6Other solid neoplasm 5Gastrointestinal 5Tumor-Agnostic 3CNS 3Thoracic 2Dermatologic 2Other neoplasm 1

Conditions

Neoplasms 2Neoplasm Metastasis 1Carcinoma 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × liposomal doxorubicin × Tumor-Agnostic × Clear all
NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
38 enrolled
Tumor-Agnostic

Neoplasms

NCT00761644 2019-04-11

Doxil, Bevacizumab and Temsirolimus Trial

M.D. Anderson Cancer Center

Phase 1 Completed
200 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00183742 2014-05-22

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

University of Southern California

Phase 1 Completed
35 enrolled
Tumor-Agnostic

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡